undamentalytics Newsletter

Malley Thomas: insider trades

Director at 5 companies we cover. 9 open-market purchases and 1 sale not made under a pre-set plan, reported from June 11, 2012 to August 14, 2025.

Would copying Malley Thomas’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 9 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on June 12, 2012 into $36,757 by November 2, 2026, +9.5% a year. The copy held shares only 39% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $30,682, +8.1% a year (the S&P 500 held throughout made $73,116, +14.9% a year). Beta against the index was 0.26. Twelve months after each report, the average purchase was +54.0% against the S&P 500 (median +68.0%), and 56% beat it. Measured from the trade date, the insider’s own timing, the average was +44.1%. After their sales, the shares moved +117.5% against the index over 12 months on average (a negative figure means selling was the right call); 0% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20122014201620182020202220242026 $73.1k$36.8k$30.7k
Copying Malley ThomasS&P 500, same days investedS&P 500, held throughout $10,000 copying Malley Thomas’s open-market purchases from June 12, 2012, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+9.5%
S&P 500, same days invested
+8.1% (held throughout +14.9%)
Time in shares
39%
Sharpe ratio (S&P 500)
0.38 (0.81)
Biggest drop (S&P 500)
−94% (−34%)
Market sensitivity (beta)
0.26
Purchases copied
9

Trade by trade

Malley Thomas: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 9 −2.9% +3.9% 56% 5 0.25 0.82 No reliable evidence
Purchases, 6 months after the report 9 +1.4% +5.6% 56% 5 0.09 0.93 No reliable evidence
Purchases, 12 months after the report 9 +54.0% +68.0% 56% 5 1.32 0.26 No reliable evidence
Purchases, 12 months after the trade 9 +44.1% +57.6% 56% 5 1.17 0.31 No reliable evidence
Sales, 3 months after the report 1 +16.0% +16.0% 0% 1 — — Not enough years
Sales, 12 months after the report 1 +117.5% +117.5% 0% 1 — — Not enough years
Sales, 12 months after the trade 1 +115.1% +115.1% 0% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Puma Biotechnology, Inc. PBYI —30June 11, 2012October 25, 2012
Tempest Therapeutics, Inc. TPST —30March 20, 2013April 9, 2015
Kura Oncology, Inc. KURA —20December 17, 2015June 21, 2023
Beone Medicines Ltd. ONC —10November 28, 2016November 28, 2016
Kiniksa Pharmaceuticals International, plc KNSA —01August 14, 2025August 14, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 14, 2025August 12, 2025 KNSA Sale $5,859,815 +16.0%+117.5%+115.1%
June 21, 2023June 16, 2023 KURA Purchase $575,000 −16.0%+68.0%+57.6%
November 28, 2016November 23, 2016 ONC Purchase $960,000 +18.4%+141.4%+153.0%
December 17, 2015November 10, 2015 KURA Purchase $400,000 −47.0%−38.8%−47.9%
April 9, 2015April 8, 2015 TPST Purchase $142,500 −13.4%−68.0%−64.9%
January 15, 2015January 13, 2015 TPST Purchase $1,750,000 −45.1%−81.9%−82.6%
March 20, 2013March 18, 2013 TPST Purchase $450,000 +34.1%−18.8%−28.0%
October 25, 2012October 24, 2012 PBYI Purchase $160,000 +33.6%+109.6%+72.4%
June 13, 2012June 11, 2012 PBYI Purchase $125,400 +3.9%+190.4%+166.7%
June 11, 2012June 7, 2012 PBYI Purchase $124,600 +5.5%+183.9%+170.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Malley Thomas traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.